A study in Taiwan involving over 220,000 patients with type 2 diabetes found that the combination of glucagon-like peptide 1 receptor agonists and thiazolidinediones led to an 80% lower risk of all-cause mortality and major adverse cardiovascular events. The researchers used Taiwan's National Health Insurance Research Database to analyze the data and highlighted the potential benefits of combination therapy, although caution is advised due to the observational nature of the study.

Source: JAMA Network Open